Table 2. Kidney Function Loss in Control Patients Receiving Optimized Supportive Care Across Different IgAN Trials.
UPCR = Urine protein-to-creatinine ratio, UACR = Urine albumin-to-creatinine ratio, eGFR = Estimated glomerular filtration rate, IgAN = IgA nephropathy, RAASI = Renin-angiotensin-aldosterone system inhibitor, SD = Standard deviation, CI = Confidence interval
| Trial | Treatment Arm | n | Age (years) | Systolic BP (mm Hg) | Diastolic BP (mm Hg) | UPCR, g/g | Median UACR, g/g (IQR) | Median Proteinuria, g/24h (IQR) | eGFR (mL/min/1.73 m²) | Median time since IgAN diagnosis (years) | Total eGFR slope (mL/min/1.73 m²/year) |
| Manno et al. [38] | Active control (ramipril) | 49 | 35 (11) | 123 (8) | 82 (7) | N/A | N/A | 1.5 (1.4–2.3) | 98 (28) | ≤1 year before randomization | –6.2 (SD±13.3) |
| TESTING [39] | Placebo + RAASI | 246 | 37 (29–46) | 125 (116–131) | 80 (74–86) | N/A | N/A | 1.9 (1.4–2.9) | 59 (48–72) | 0.4 (0.3–1.2) | –5.0 (95% CI –6.1 to –3.9) |
| STOP-IgAN [40] | 10-year results RAASI | 80 | 45 (12)b | 126 (10)b | 78 (8)b | 1.1 (0.6)b | 1.1 (0.6)b | 1.7 (0.8)b | 59 (27) | N/A | –2.7 (SD±2.0) |
| PROTECT [41] | Active control (irbesartan) | 202 | 45 (12) | 130 (12) | 83 (11) | 1.2 (0.9–1.7) | 1.2 (0.9–1.7) | 1.8 (1.3–2.6) | 57 (24) | 4.0 (1.0–10.0) | –3.9 (95% CI –4.6 to –3.1) |
| DAPA-CKD [42] | Placebo + RASI | 133 | 50 | 132 (14) | 84 (12) | N/A | N/A | N/A | 43 (8) | N/A | –4.7 (SD±0.5) |
| NefigArd [43] | Placebo + RASI | 182 | 42 (34–49) | 124 (117–130) | 79 (74–84) | 1.3 (0.9–1.7) | 1.3 (0.9–1.7) | 1.8 (1.0–2.5) | 55 (46–64) | 2.6 (0.6–6.5) | –5.4 |